Introduction

CHARGE (Coloboma, Heart defects, Atresia choanae (nasal passage blockage), Retardation of growth and development, Genital abnormalities, and Ear anomalies) syndrome is a rare, multisystem developmental disorder with a unique set of congenital anomalies that consist of coloboma of the eye, heart malformations, atresia of the choanae, growth retardation and developmental delay, genital abnormalities, and ear deformities. Most patients are linked with mutations of the CHD7 (Chromodomain Helicase DNA-binding protein 7) gene, coding a chromodomain helicase DNA-binding protein essential for chromatin remodeling and regulation of genes during embryogenesis.¹ Although the genetic origin of CHARGE syndrome has been clearly outlined, the pathogenic mechanisms that link CHD7 dysfunction and the broad range of developmental abnormalities are not yet fully understood. In recent years, advances in epigenetics also emphasised that changes in the structure of chromatin through DNA methylation, and histone modification have a key function in regulating gene expression, especially embryonic development. Thus it is critical to understand epigenetic regulation of CHARGE syndrome to explain the gap between genotype and phenotype, providing new understanding of pathogenesis and of potential therapy.²

CHARGE syndrome: Clinical and genetic foundation

CHARGE syndrome is characterised by a typical set of clinical findings encapsulated in the acronym "CHARGE": coloboma, heart abnormalities, choanae atresia, growth retardation, hypoplasia of the genitals, and ear dysmorphisms, although other malformations such as craniofacial dysmorphisms, tracheoesophageal fistula, and mental delays are also frequent.³ Diagnosis is often based on clinical signs and symptoms, and prominent features including ocular coloboma, choanal atresia, and dysfunction of cranial nerves have greater diagnostic significance.

 Genetically, most patients have one copy of a mutated CHD7 gene, which produces a protein important for the formation of neural crest cells. In rare cases, mutations in other genes, such as SEMA3E and KMT2D, are involved. Notably, genotype-phenotype correlations are still heterogeneous: truncating CHD7 mutations are generally associated with more severe multisystem anomalies, while missense mutations are more likely to produce milder or unusual phenotypes. This heterogeneity underlines the influence of genetic background and epigenetic regulation in determining the clinical presentation of CHARGE syndrome.²

Basics of epigenetic control

Epigenetic control involves heritable but reversible changes that affect gene expression without changing the DNA sequence itself. DNA methylation, one of the best-characterised mechanisms of epigenetic control, frequently occurs at cytosines (a type of DNA building block) within regions called CpG islands, which are stretches of DNA that is rich in certain chemical patterns. It suppresses gene expression by blocking the binding of transcription factors or attracting methyl-binding proteins, thus helping to regulate genes in a tissue-specific and developmentally programmed manner. Histone modifications, such as acetylation, methylation, and phosphorylation, also regulate chromatin accessibility, wherein active euchromatin structures facilitate transcription and condensed heterochromatin structures silence gene expression. Concurrently, non-coding RNAs, like microRNAs and long non-coding RNAs, refine transcriptional and post-transcriptional processes by binding to chromatin modifiers or degrading mRNA. Coupled together, these epigenetic mechanisms direct the spatiotemporal patterns of gene expression necessary for embryonic development.^4,5

CHD7 as an epigenetic regulator

The key gene in CHARGE syndrome is the CHD7 gene that encodes for a member of the chromodomain helicase DNA-binding protein family. At a structural level, CHD7 has chromodomains, an ATPase/helicase domain, and DNA-binding motifs that allow it to remodel chromatin in an ATP-dependent fashion. At a functional level, CHD7 controls transcription through the regulation of nucleosome positioning and the recruitment of transcriptional machinery to develop gene loci.⁶ Notably, CHD7-mediated chromatin remodeling is essential for regulating neural crest cell migration and differentiation, both of which are directly involved in craniofacial, cardiac, and sensory organ development. In addition to chromatin remodeling, CHD7 is also embedded in downstream signal transduction networks, such as retinoic acid and Wnt signaling pathways, thus impacting various developmental networks. Dysregulation of these processes by CHD7 mutations disrupts the epigenetic landscape, causing global transcriptional dysregulation and contributing to phenotypic diversity in CHARGE syndrome.⁷

Epigenetic processes in developmental abnormalities of CHARGE syndrome

Epigenetic dysregulation resulting from CHD7 mutations is a pivotal mechanism underlying a wide range of developmental abnormalities in CHARGE syndrome. Throughout embryogenesis, neural crest cells responsible for forming craniofacial structures, cardiac outflow tracts, and peripheral nerves are particularly reliant on CHD7-mediated chromatin remodeling. Disrupted regulation causes aberrations in neural crest cell migration and differentiation, leading to craniofacial abnormalities including cleft lip, defective palate, and dysmorphic features.⁷

Likewise, CHD7 plays a critical role in sensory organ development, and CHD7 dysfunction disrupts the epigenetic regulation of genes engaged in inner ear morphogenesis and olfactory system development, with consequences including hearing loss, semicircular canal defects, and anosmia, which are the signature features of CHARGE syndrome.⁸

In the cardiovascular system, defective CHD7 activity disrupts transcriptional networks governing neural crest–derived cardiac structures, leading to conotruncal heart defects and vascular malformations. In addition, CHD7 affects transcriptional programs of the hypothalamic-pituitary-gonadal axis, and its disruption has been associated with reproductive and endocrine abnormalities, such as hypogonadotropic hypogonadism and delayed puberty. Overall, these results emphasise that dysregulated epigenetic control in numerous developmental pathways underlies the multisystem phenotype of CHARGE syndrome.⁹

Experimental and clinical evidence

Experimental models have played a crucial role in demonstrating the function of CHD7 during development. Zebrafish knockdown models for CHD7 exhibit craniofacial malformations, semi-circular canal defects, and defective neural crest migration, which closely resemble CHARGE syndrome features10. Mouse models with heterozygous CHD7 mutations also exhibit inner ear malformations, cardiac defects, and olfactory impairments, shedding light on tissue-specific requirements for CHD7 in embryogenesis.^11,12 In humans, epigenomic analysis of CHARGE patients shows broad perturbation of chromatin accessibility and enhancer activity, especially at developmentally regulated genes that are controlled by CHD7. These observations indicate that CHD7 mutations have global impacts on the chromatin landscape, connecting gene regulatory impairments to multisystem abnormalities. Besides, progress in molecular profiling has identified new biomarkers such as CHD7-associated transcriptional signatures that, in the future, can potentially enhance diagnosis, prognosis, and risk stratification in CHARGE syndrome.

Therapeutic implications of epigenetic regulation

As CHD7 occupies a central position in chromatin remodeling, therapeutic strategies are seeking epigenetic-based remedies to reinstate transcription balance. Small molecule inhibitors of histone acetyltransferases, deacetylases, and methyltransferases are being explored for their potential to modulate chromatin accessibility in related developmental disorders, opening the possibility of therapeutic application in CHARGE syndrome. Nevertheless, there are significant hurdles to targeting chromatin remodeling pathways owing to their pleiotropic (a gene with multiple effects on the phenotype) actions and potential off-target regulation of gene expression. Personalised interventions that incorporate patient-specific genetic and epigenetic information can inform future drug development, providing prospects for individualised therapies that restore dysregulated developmental pathways.¹³

Future directions and research gaps

Although progress has been made, there are still major gaps in characterising the epigenetic basis of CHARGE syndrome. Convergence of genomics and epigenomics will be essential for the CHD7-dependent regulatory circuits and accounting for phenotypic heterogeneity. In addition, the contribution of environmental epigenetic modifiers, including maternal diet and in utero exposures, must be investigated, as these might either worsen or improve developmental outcomes. Lastly, longitudinally designed patient studies are required to determine how epigenetic alterations unfold over time and how they relate to clinical severity, treatment response, and long-term outcome.¹³

Summary

Epigenetic control is central to bridging CHD7 mutations with varied clinical presentations of CHARGE syndrome. Studies in models and patients have shown that CHD7 is a master controller of chromatin remodeling that regulates neural crest formation, sensory organ development, and cardiovascular patterning. As no specific treatments are available, advances in the emerging field of epigenetics provide hopeful pathways for biomarker identification and future therapeutic development. A greater insight into how genetic and epigenetic contributions interact will be necessary to move precision medicine strategies forward to enhance outcomes in patients with CHARGE syndrome.

FAQs

How do CHD7 mutations lead to such a broad spectrum of developmental anomalies in CHARGE syndrome?

CHD7 is a chromatin remodeler that controls the accessibility of crucial developmental genes. Disruptions in epigenetic regulation impact neural crest cell migration, sensory organ development, cardiovascular development, and endocrine function. Due to its activity in multiple tissues and stages of development, CHD7 dysfunction generates the multisystem anomalies observed in CHARGE syndrome.

Will epigenetic understanding of CHARGE syndrome enhance clinical management?

Yes. Identifying how epigenetic dysregulation plays a role in disease mechanisms can inform biomarker discovery for earlier diagnosis, prognosis prediction, and potential therapeutic targets. For instance, epigenomic analysis of patients might uncover patterns that enable clinicians to tailor surveillance and treatment approaches.

Are there potential therapies for targeting epigenetic regulation in CHARGE syndrome?

Although there are no epigenetic-targeting therapies yet approved for CHARGE, studies on drugs that target chromatin remodeling, histone marks, or DNA methylation are in progress. The challenge is to develop therapy that would restore CHD7-related pathways without significantly changing epigenetic regulation, but precision medicine strategies in the future are promising.